New hope for tough cancers: first patients to receive experimental drug

NCT ID NCT07436728

Not yet recruiting Disease control Sponsor: Takeda Source: ClinicalTrials.gov ↗

Summary

This is the first time a new drug called TAK-505 is being given to people. The study aims to find a safe and effective dose for adults with advanced solid tumors—specifically certain stomach, lung, bowel, and head/neck cancers that have spread and are no longer responding to standard treatments. Researchers will closely monitor how the body handles the drug and if it can help shrink or control the cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Baylor College of Medicine

    Houston, Texas, 77030, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Cleveland Clinic Foundation

    Cleveland, Ohio, 44195, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • H Lee Moffitt Cancer Center

    Tampa, Florida, 33612, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Icahn School of Medicine at Mount Sinai

    New York, New York, 10029, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • MD Anderson

    Houston, Texas, 77030, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Mary Crowley Cancer Center

    Dallas, Texas, 75230, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • NEXT Oncology

    San Antonio, Texas, 78229, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • NEXT Oncology

    Fairfax, Virginia, 22031, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Sarah Cannon Research Institute SCRI

    Nashville, Tennessee, 37203, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Seattle Cancer Care Alliance

    Seattle, Washington, 98109, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Tennessee Oncology

    Nashville, Tennessee, 37203, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • UCI Health

    Orange, California, 92868, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Univeristy of Minnesota

    Minneapolis, Minnesota, 55455, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of California San Diego Medical Center, La Jolla

    San Diego, California, 92093, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of California San Francisco

    San Francisco, California, 94143, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.